

# Identifying the best treatment choice for relapsing/refractory glioblastoma: a systematic review with multiple Bayesian network meta-analyses

Francesco Schettini<sup>\*1,2,3</sup>, Estela Pineda<sup>1,2</sup>, Andrea Rocca<sup>4,5</sup>, Victoria Buché<sup>4</sup>, Carmine Antonio Donofrio<sup>6,7</sup>, Manuel Mazariegos<sup>1</sup>, Benvenuto Ferrari<sup>8</sup>, Richard Tancredi<sup>8</sup>, Stefano Panni<sup>8</sup>, Marika Cominetti<sup>6</sup>, Alberto Di Somma<sup>9</sup>, Josep González<sup>9</sup>, Antonio Fioravanti<sup>6</sup>, Sergio Venturini<sup>†,10</sup>, Daniele Generali<sup>\*,†,4,8</sup>

<sup>1</sup>Medical Oncology Department, Hospital Clinic of Barcelona, 08036, Barcelona, Spain,

<sup>2</sup>Translational Genomics and Targeted Therapies in Solid Tumors Group, Clinic Barcelona Research Foundation-August Pi i Sunyer Biomedical Research Institute (FRCB-IDIBAPS), 08036, Barcelona, Spain,

<sup>3</sup>Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, 08036, Spain,

<sup>4</sup>Department of Medical, Surgical and Health Sciences, University of Trieste, 34147 Trieste, Italy,

<sup>5</sup>Hospital of Cattinara, University of Trieste, Trieste, 34149, Italy,

<sup>6</sup>Neurosurgery, ASST Cremona, 26100 Cremona, Italy,

<sup>7</sup>Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy,

<sup>8</sup>Breast and Brain Unit, ASST Cremona, 26100 Cremona, Italy,

<sup>9</sup>Department of Neurosurgery, Hospital Clinic of Barcelona, Barcelona, 08036, Spain,

<sup>10</sup>Department of Economic and Social Sciences, Catholic University of Sacred Heart - Cremona Campus, 26100 Cremona, Italy

\*Corresponding authors. Daniele Generali, MD, PhD, Department of Medicine, Surgery and Health Sciences, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy. E-mail: [dgeneral@units.it](mailto:dgeneral@units.it); Francesco Schettini, MD, PhD, Medical Oncology Department, Hospital Clinic of Barcelona, Faculty of Medicine and Health Sciences, University of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors Group, FRCB-IDIBAPS, C. Villaruel 170, 08036 Barcelona, Spain. E-mail: [schettini@recerca.clinic.cat](mailto:schettini@recerca.clinic.cat); [schettini@ub.edu](mailto:schettini@ub.edu).

†Co-last authors.

## Abstract

**Background:** Glioblastoma is a highly aggressive primary central nervous system tumor characterized by poor outcomes. In case of relapse or progression to adjuvant chemotherapy, there is no univocal preferred regimen for relapsing glioblastoma.

**Methods:** We conducted a systematic review and Bayesian trial-level network meta-analyses (NMA) to identify the regimens associated with the best outcomes. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS) and overall response rates (ORR). We estimated separate treatment rankings based on the surface under the cumulative ranking curve values. Only phase II/III prospective comparative trials were included.

**Results:** Twenty-four studies (3733 patients and 27 different therapies) were ultimately included. Twenty-three different regimens were compared for OS, 21 for PFS, and 26 for ORR. When taking lomustine as a common comparator, only regorafenib was likely to be significantly superior in terms of OS (hazard ratio: 0.50, 95% credible interval: 0.33-0.75). Regorafenib was significantly superior to other 16 (69.6%) regimens, including NovoTTF-100A, bevacizumab monotherapy, and several bevacizumab-based combinations. Regarding PFS and ORR, no treatment was clearly superior to the others.

**Conclusions:** This NMA supports regorafenib as one of the best available options for relapsing/refractory glioblastoma. Lomustine, NovoTTF-100A, and bevacizumab emerge as other viable alternative regimens. However, evidence on regorafenib is controversial at best. Moreover, most studies were underpowered, with varying inclusion criteria and primary endpoints, and no longer adapted to the most recent glioblastoma classification. A paradigmatic change in clinical trials' design for relapsing/refractory glioblastoma and more effective treatments are urgently required.

**Key words:** glioblastoma; regorafenib; bevacizumab; network meta-analysis; Bayesian.

## Implications for Practice

This is the most updated network meta-analysis on prospective phase II/III trials in the setting of relapsing/refractory glioblastoma, and the first to include randomized trials with immunotherapy or re-irradiation. An attempt to provide clinicians with treatment rankings based on overall survival, progression-free survival, and overall response rates was carried out. Study results support regorafenib as the best therapeutic option in this context, with lomustine and bevacizumab-based regimens being viable alternatives. However, where our study mostly succeeds, is in pointing out the intrinsic limitations of published literature in refractory/relapsing glioblastoma, supporting recruitment in clinical trials as the preferential approach, and advocating for a paradigmatic change in how we design studies to tackle this prognostically unfavorable disease.

Received: 23 February 2024; Accepted: 11 November 2024.

© The Author(s) 2024. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [reprints@oup.com](mailto:reprints@oup.com) for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

## Introduction

Glioblastoma is a highly aggressive primary central nervous system (CNS) tumor.<sup>1</sup> Despite increasing knowledge of its biology, the median overall survival (OS) of patients affected by glioblastoma is roughly 15 months for newly diagnosed lesions, depending on MGMT mutational status.<sup>2</sup> The standard-of-care is usually represented by surgical resection of the tumor lesion when feasible, followed by adjuvant radiotherapy with concurrent and subsequent chemotherapy with temozolomide for 6 cycles, with or without alternating electric field therapy.<sup>3-5</sup> However, tumor recurrence occurs almost always, with an average OS usually not exceeding 5-7 months after relapse.<sup>2</sup> Numerous efforts are ongoing to improve the survival outcome of patients affected by primary and recurrent glioblastoma. Although in the adjuvant setting a clear therapeutic standard exists,<sup>3-5</sup> there is no univocal standard-of-care for relapsing glioblastoma. In this case, either surgery, radiotherapy, monochemotherapy, or polichemotherapy with alkylating agents and/or target therapies with antiangiogenic agents (bevacizumab or regorafenib, where approved) are a feasible option.<sup>6</sup> Yet, survival remains poor, with a 2-year and 5-year survival rate of 30% and 10%, respectively.<sup>2,7</sup>

Given the uncertainty regarding the best treatment strategy and the lack of direct comparisons in randomized clinical trials (RCTs) among the most commonly adopted regimens, we decided to conduct a network meta-analysis (NMA) to evaluate the activity and efficacy of all available therapeutic strategies tested for recurrent/refractory glioblastoma in prospective comparative studies and generate a ranking of treatments based on the surface under the cumulative ranking (SUCRA) curve method.<sup>8,9</sup>

## Materials and methods

### Literature search and inclusion criteria

A systematic literature review was performed on August 13, 2024 on PUBMED and Cochrane CENTRAL in order to identify prospective phase II or III comparative studies evaluating the anti-tumoral activity and clinical efficacy of local and systemic oncologic treatments for refractory/relapsing glioblastoma in adult patients. No language, nor time restrictions were adopted. We followed the recommendations of the Cochrane Collaboration, in order to identify all relevant published and unpublished trials. The search strategy was based on the use of a combination of disease, treatment, and study design terms. The full query is reported in [Supplementary Methods](#). Also, European Society for Medical Oncology (ESMO) Congress and American Society of Clinical Oncology (ASCO) annual meeting online proceedings were consulted, along with references to the latest ESMO, ASCO, and US National Comprehensive Cancer Network (NCCN) guidelines.<sup>3-5</sup> Two reviewers (V.B., F.S.) independently evaluated each identified single study against the established predetermined criteria, and a third reviewer (DG) was consulted in case of controversy.

Study inclusion criteria were:

1. Prospective comparative phase II or III trials;
2. Availability or computability from published data of hazard ratios (HR) for OS and/or progression-free survival (PFS) and/or objective response data to calculate odds ratios (OR) for overall response rate (ORR).

### Study endpoints and data extraction

The primary endpoint was OS. Secondary endpoints were PFS and ORR. Objective responses in included trials were defined according to the MacDonald Criteria<sup>10</sup> or RANO Criteria (for studies published after their introduction in 2010),<sup>11</sup> depending on the year of study design and conduction.

From each included publication, details were extracted on study design, study population characteristics and interventions, previous treatments, and MGMT mutational status. The HR for PFS and OS and associated 95% CIs were extracted or computed by extrapolating data from digitalized Kaplan-Meier curves.<sup>12</sup> OR and associated 95% CI for ORR were calculated based on the published objective response data.

When phase I/II was reported in the same publication, only phase II data from comparative studies was used.

### Statistical analyses

A Bayesian trial-level NMA framework was adopted for each endpoint, for a total of 3 networks (OS, PFS, and ORR).<sup>13-15</sup> Treatment rankings for each endpoint were obtained with the SUCRA method. The SUCRA values range from 0% to 100%. A higher SUCRA value indicates a greater likelihood that a therapy ranks at the top, while a SUCRA value closer to 0 suggests a higher likelihood that the therapy ranks at the bottom.<sup>9</sup> The HR for PFS and OS and the OR for ORR with their respective Bayesian 95% credible intervals (CrI) were estimated using a Markov Chain Monte Carlo method as implemented in the WinBUGS software package.<sup>13</sup> For all the analyses, the WinBUGS sampler, using 3 chains, was run for 1 000 000 iterations that were discarded as “burn-in,” and the model was run for a further 2 000 000 iterations on which inferences were based. A thinning rate of 100 iterations was used to reduce autocorrelation of the sampled values, thus leaving 20 000 iterations per chain to use for estimation and inference. Convergence of the chains was confirmed by the Gelman-Rubin statistic and by inspection of the trace plots. For each NMA, the model providing the best fit to the data between random- and fixed-effect was chosen based on the deviance information criterion (DIC). The DIC provides a measure of model fit that penalizes model complexity. The model with the lowest DIC was considered to provide the best fit to the data. When DIC values were similar (difference of <5), a fixed-effect model was preferred.<sup>13,16,17</sup> For the NMA of the HR, we assumed that the logHR was normally distributed with the logHR mean equaling the true logHR observed in each study, and the variance equaling the observed variability in each study. We used a vague flat (ie, uniform) prior distribution for between-study SD  $\tau$ . Moreover, as for the correlations between the random effects for each trial, we adopted the standard approach to set this correlation equal to 0.5.<sup>8</sup> We used a common between-study variance parameter  $\tau^2$  for all studies.


The PRISMA guidelines for NMA were followed.<sup>18</sup> Inconsistency of the results was explored, as recommended.<sup>18-20</sup> For all treatment line networks according to each endpoint, an inconsistency model was obtained by omitting the consistency equations. Then, for each endpoint, the consistency and inconsistency models were compared in terms of goodness of fit by using their relative DIC.<sup>19,20</sup> A difference of less than 5 points was considered to be not significant.

All the analyses were performed with WinBUGS version 1.4.3 and the results were processed using R version 4.2.0.<sup>13,21</sup> All the equations adopted had been published elsewhere and adapted for our analyses.<sup>8</sup> The risk of bias for each trial was assessed by using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.<sup>22</sup> Internal validity of eligible studies was assessed according to the Cochrane Collaboration’s “Risk of Bias” tool in Review Manager<sup>23</sup> (RevMan 5, <http://tech.cochrane.org/revman>).

A formal review protocol was not prepared. This study was registered in the Open Science Framework online public database, registration DOI: 10.17605/OSF.IO/UMF8C.

## Results

Overall, 18 415 references were screened. Among them, only 45 were prospective interventional comparative phase II and III studies concerning refractory/relapsing GB.<sup>24-68</sup> However, based on the available published data and treatment type, 24 studies could be ultimately included in our analyses (Figure 1),<sup>24,28,30,31,33-35,39,42-44,46,47,49,51-55,60-64</sup> for a total of 3733 patients and 27 different therapies. The median age of patients in the included studies was 56.3 years (interquartile range [IQR]: 55.0-63.1). Eighteen (75.0%) trials were phase II and 6 (25.0%) were phase III, with 1 phase II trial being non-randomized (5.6%).<sup>54</sup> A total of 4 (16.7%) studies included patients in 2nd or further lines,<sup>42,46,51,60</sup> while the



**Legend.** OS: overall survival; PFS: progression-free survival; ORR: overall response rate; GB: glioblastoma.

**Figure 1.** PRISMA flow-chart. Abbreviations: GB, glioblastoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.

**Table 1.** Main characteristics of the included studies.

First author	Line	Phase	Randomized	N. Arms	Treatments	Centers	N. patients	Age (median years)	Primary endpoint(s)	Bevacizumab-pretreated	MGMT-methylated (%)	IDH1/2-mutant (%)	EGFRvIII (%)
Batchelor 2013 J Clin Oncol	2nd	III	Yes	3	Cediranib vs Cediranib + Lomustine vs Lomustine	Multicenter	325	54, 54, 54	PFS	No	—	—	—
Brandes 2016 Neuro-Oncology	2nd	II	Yes	3	Galunisertib + Lomustine vs Galunisertib vs Lomustine	Multicenter	158	58, 58, 58	OS	No	—	3.8, 10.3, 2.5	—
Brown 2016 PLOS One	2nd	II	Yes	2	Cediranib + Gefitinib vs Cediranib	Multicenter	38	55, 61	PFS	No	—	—	—
Cloughesy 2017 J Clin Oncol	2nd	II	Yes	2	Bevacizumab + Onartuzumab vs Bevacizumab	Not reported	129	57, 55	PFS	No	37.5, 48.1	6.9, 8.8	—
Field 2015 Neuro-Oncology	2nd	II	Yes	2	Bevacizumab + Carboplatin vs Bevacizumab	Multicenter	122	55, 55	PFS	No	—	—	—
Friedman 2019 J Clin Oncol	2nd	II	Yes	2	Bevacizumab vs Bevacizumab + Irinotecan	Multicenter	167	54, 57	6-month PFS and ORR	No	—	—	—
Gilbert 2016 J Neurooncol	2nd	II	Yes	2	Bevacizumab + Irinotecan vs Bevacizumab + Temozolomide	Not reported	117	55, 58	6-month PFS	Allowed	—	—	—
Reardon 2011 J Neurooncol	2nd	II	Yes	2	Bevacizumab + Temozolomide vs Bevacizumab + Etoposide	Single center	23	50.8, 52.4	6-month PFS	Allowed	—	—	—
Tsien CI 2022 J Clin Oncol	≥2nd	II	Yes	2	Bevacizumab + Radiotherapy vs Bevacizumab	Multicenter	170	60, 57	OS	Unclear, but mostly no	20.9, 14.3	—	—
Stupp 2012 Europ J Can	2nd	III	Yes	2	NovoTTF-100A vs Bevacizumab/Lomustine/Other	Multicenter	237	54, 54	OS	Yes (19% and 18%)	—	—	—
Taal 2014 Lancet Oncol	2nd	II	Yes	4	Bevacizumab vs Lomustine vs Bevacizumab + Lomustine 90mg/m2 vs Bevacizumab + Lomustine	Multicenter	153	58, 56, 53, 58	9-month OS	No	43.0, 53.0, 46.0, 33.0	3.0, 7.0, 10.0, 0.0	—
Weathers 2016 J Neurooncol	2nd	II	Yes	2	Bevacizumab vs LD Bevacizumab + Lomustine	Single center	71	—	PFS	No	—	—	—
Wick 2010 J Clin Oncol	2nd	III	Yes	2	Enzastaurin vs Lomustine	Multicenter	266	—	PFS	No	—	—	—
Wick 2017 New Eng J Med	2nd	III	Yes	2	Bevacizumab + Lomustine vs Lomustine	Multicenter	437	—	OS	No	23.3, 24.8	—	—
Brandes 2019 The Oncologist	≥2nd	II	Yes	2	Bevacizumab + Lomustine vs Lomustine	Multicenter	123	56, 58.5	OS	No	19.4, 18.0	—	—
Lombardi 2019 Lancet Oncol	2nd	II	Yes	2	Regorafenib vs Lomustine	Multicenter	119	54.8, 58.9	OS	Allowed	49.0, 46.0	5.0, 0.0	—
Reardon 2017 Cancer	2nd	II	No	2	Trebananib vs Bevacizumab + Trebananib	Multicenter	48	61.9, 63.1	6-month PFS	No	18.1, 8.1	18.1, 5.4	—

Table 1. Continued

First author	Line	Phase	Randomized	N. Arms	Treatments	Centers	N. patients	Age (median years)	Primary endpoint(s)	Bevacizumab-pretreated	MGMT-methylated (%)	IDH1/2-mutant (%)	EGFRvIII (%)
Reardon 2020 JAMA Oncol	2nd	III	Yes	2	Nivolumab vs Bevacizumab	Multicenter	369	55.5, 55	OS	No	23.4, 22.7	—	—
Bota 2018 Future Medicine	2nd	II	Yes	2	Bevacizumab + ERC1671 (Gliovac) vs Bevacizumab	Not reported	9	—	OS	No	—	0.0, 0.0	—
Cloughesy 2020 Neuro-Oncology	≥2nd	III	Yes	2	Bevacizumab + VB-111 vs Bevacizumab	Multicenter	256	—	OS	No	15.6, 20.3	10.2, 9.4	20.3, 18.8
Galanis 2019 Cancer	2nd	II	Yes	2	Bevacizumab + Dasatinib vs Bevacizumab	Multicenter	121	58, 56.5	6-month PFS	No	—	—	—
Lee 2020 Cancer	2nd	II	Yes	2	Bevacizumab + Trebananib vs Bevacizumab	Multicenter	115	57, 58	6-month PFS	No	—	—	—
Puduvalli 2020 Neuro-Oncology	2nd	II	Yes	2	Bevacizumab + Vorinostat vs Bevacizumab	Multicenter	87	—	PFS	No	—	—	—
Reardon 2020 Clin Can Res	2nd	II	Yes	2	Rindopepimut + Bevacizumab vs Bevacizumab	Multicenter	73	59, 55	6-month PFS	No	—	—	100.0, 100.0

Abbreviations: LD, low dose; ORR, objective response rates; OS, overall survival; PFS, progression-free survival; RT, radiotherapy.

rest were 2nd-line trials. In all studies, patients had previously received temozolomide. Bevacizumab, alone or in combination, was the most common therapeutic agent adopted. Previous administration was clearly allowed only in 4 studies,<sup>35,39,43,55</sup> in 2 (50.0%) of these a bevacizumab-containing regimen was assessed, in another 1 (25.0%) a tyrosine kinase inhibitor (TKI) with anti-angiogenic activity (ie, regorafenib) was tested. In one study, previous bevacizumab administration status was not specified, but most patients (80.6%) were treated with a bevacizumab-containing regimen at their first relapse, suggesting most had not received it, yet.<sup>42</sup> To note, to include NovoTTF-100A in the networks, the active control in Stupp et al was assumed to be bevacizumab monotherapy, considering that this was the most frequent therapeutic option adopted in the trial.<sup>43</sup>

MGMT methylation, IDH1/2 mutations, and EGFRvIII expression, which are all currently well-known glioblastoma molecular prognostic and/or predictive biomarkers, had been assessed in 9 (37.5%),<sup>31,42,44,49,51,52,54,55,60</sup> 8 (33.3%),<sup>28,31,42,44,53-55,60</sup> and 2 (8.3%)<sup>60,61</sup> studies, respectively. The median percentage of MGMT promoter methylated glioblastoma was 23.4% (IQR: 19.1-43.8%). The median percentage of IDH-mutant glioblastoma was 6.9% (IQR: 2.9%-10.2%). In Reardon et al all glioblastoma had to be positive for EGFRvIII, either in the primary or the relapsing tumor,<sup>61</sup> while in Cloughesy et al approximately 20% of cases were EGFRvIII-positive.<sup>60</sup>

Study characteristics are resumed in Table 1.

### Primary endpoint: overall survival


For the OS network, a fixed-effect model turned out to be the best-fitting model based on DIC. Overall, 23 different treatments were compared (Figure 2).

When taking lomustine monotherapy as a common comparator, we observed that only regorafenib (HR: 0.50, 95%CrI: 0.33-0.75) was likely to be significantly superior in terms of OS (Figure 3). Regorafenib was likely to be significantly superior to 16 (69.6%) regimens, including NovoTTF-100A (HR: 0.53, 95%CrI: 0.28-0.98), nivolumab (HR: 0.44, 95%CrI: 0.24-0.79), bevacizumab monotherapy (HR: 0.46, 95%CrI: 0.26-0.80) or combined with lomustine (HR: 0.54, 95%CrI: 0.34-0.86), carboplatin (HR: 0.39, 9%CrI: 0.20-0.75), or re-irradiation (HR: 0.47, 95%CrI: 0.24-0.90). The TKI was the best treatment choice according to the SUCRA-based ranking (Figure 3). According to SUCRA, lomustine ranked 5th when considering only approved therapies, and was superior to bevacizumab monotherapy (Figure 3). The direct comparison between the 2 therapies did not show a significantly different association with OS (HR: 0.83, 95%CrI: 0.61-1.14). To note, besides regorafenib, no other regimen among those approved for the clinical practice showed any significant superiority/inferiority to others, including bevacizumab monotherapy (not shown). There was no relevant inconsistency in the OS network model based on DIC.

### Secondary endpoint: progression-free survival and overall response rates

For the PFS and the ORR networks, a random effect model turned out to be the best-fitting model based on DIC. Respectively, 21 and 26 different regimens were compared in the former and latter networks (Figure 2). No treatment was significantly superior to lomustine monotherapy in PFS and in ORR (Figure 4). Furthermore, no treatment was likely to be





**Figure 3.** Forest plot of OS of all included regimens for relapsed/refractory glioblastoma compared to lomustine monotherapy and treatment ranking based on SUCRA. (A) A forest plot including the logHR of OS of each treatment vs lomustine monotherapy. Central dots represent posterior medians; thin lines represent 95%CrI, while thicker ones represent 80% CrI. Log scale was adopted to graphically represent the 95% CrI. The first column of values on the right reports the logHR with 95%CrI, the second column reports HR for OS with 95%CrI. Statistically significant results according to Bayesian posterior medians and 95%CrI are highlighted by asterisks. (B) Treatment ranking according to the OS endpoint, based on SUCRA values. Bar plot displaying SUCRA values for treatments analyzed in a Bayesian network meta-analysis. Each bar represents a treatment, with the height of the bar corresponding to its SUCRA value, which indicates the probability of a treatment being among the most effective options. Higher bars denote higher SUCRA values, suggesting greater effectiveness relative to other treatments. The y-axis lists the treatments, and the x-axis shows the SUCRA values as percentages. Abbreviations: BEVA, bevacizumab; CARBO, carboplatin; CED, cediranib; CrI, credible interval; DASA, dasatinib; ENZA, enzastaurin;

outcomes of the lomustine control arm likely due to the worse prognostic features of this cohort, which made the study results controversial. Additionally, some non-trivial grade (G) 3-4 toxicities like hand-foot skin reaction (10%) or neutropenia (5%) and frequent G1-2 toxicities like fatigue (24%), hypertension (22%), diarrhea (15%), and skin rash/desquamation (12%) were associated to the TKI. Our results, shed light on the performance of regorafenib when compared also to bevacizumab-based regimens and chemotherapies other than lomustine. In this perspective, our analysis seems to support a potential role for regorafenib in recurrent glioblastoma, despite the limitations previously exposed. Furthermore, regorafenib is likely less toxic than combination chemotherapies that are also administered in the refractory scenario, such as PCV, to which it could not be compared in this NMA. At the same time, regorafenib recent performance in the GBM AGILE adaptive phase II/III trial (NCT03970447) was disappointing at best, posing serious questions on its therapeutic efficacy in this context.<sup>70</sup>

According to these NMA results, bevacizumab, both in monotherapy or in combination with chemotherapy or re-irradiation, seemed not to be significantly inferior, nor superior to other treatments on all endpoints. Only in terms of OS, bevacizumab was significantly inferior to regorafenib. Noteworthy, no bevacizumab-based combination was significantly superior to bevacizumab monotherapy, despite showing a better SUCRA ranking position on all endpoints. Consequently, taking into account its potential steroid-sparing role, the availability of biosimilar drugs that significantly reduced its costs, the potential PFS benefit, and the mild toxicity profile in comparison to most single-agent chemotherapies, bevacizumab alone might be a reasonable therapeutic option in the refractory scenario, especially for patients unfit for chemotherapy or regorafenib. Less clear remains its role in combination with chemotherapy, since no specific advantages can be clearly detected. Importantly, bevacizumab sequential use after regorafenib has not been studied, whereas in the REGOMA trial bevacizumab therapy previous to regorafenib administration was allowed,<sup>55</sup> suggesting the feasibility of this sequence.


Interestingly, NovoTTF-100A, an FDA-approved medical device based on the use of electric fields applied to the tumor mass to destroy brain cancer cells, not subject to common mechanisms of antineoplastic resistance, showed in its pivotal trial comparable efficacy and activity with chemotherapy regimens commonly used for refractory/recurrent glioblastoma. Moreover, toxicity and quality of life clearly favored NovoTTF-100A over systemic anticancer agents.<sup>43</sup> In this NMA, NovoTTF-100A was the 2nd best option in the SUCRA ranking for the ORR, despite being less performing in terms of PFS and OS as compared to regorafenib and bevacizumab-based regimens. Therefore, taking into account this evidence, but also considering that this NMA is ultimately inconclusive for the lack of statistically significant results and that the same pivotal trial had the important limitation of non-centralized imaging evaluation for assessing tumor responses, we suggest that NovoTTF-100A might be an alternative option only

for selected cases, for example, when objective responses are required for symptomatic palliation.


Recent preliminary evidences show that in glioblastoma with melanoma-like *BRAF* mutations (occurring in ~3% adult cases), anti-*BRAF*/*MEK* combinations might be active therapeutic options,<sup>71</sup> which are also recommended by the NCCN guidelines as off-label treatment.<sup>4</sup> Several phase I and/or II studies are currently ongoing in this setting.<sup>71</sup> Moreover, in 1%-2% glioblastoma cases, aberrant *NTRK* fusions can be targeted with TKI entrectinib or larotrectinib, following their tumor-agnostic approval based on 2 patient-level pooled analyses of non-randomized, non-comparative phase I and II trials.<sup>4,5,72,73</sup> Unfortunately, we could not compare the performance of all these regimens, since no comparative data are available and the proportion of *BRAF*V600-mutant or *NTRK*-fusion-positive glioblastoma in all studies included in our networks is unknown. In any case, besides these limited successful examples, the vast majority of molecularly-driven therapeutic strategies hardly proved some benefit in glioblastoma. To promote more effective personalized treatment strategies, numerous efforts have been made in recent years to improve our knowledge concerning glioblastoma biology. The Cancer Genome Atlas Research Network described recurrent genomic abnormalities in glioblastoma in 2008 and the methylation of *MGMT* promoter was found to be associated with sensitivity to alkylating agents.<sup>74</sup> A subsequent seminal work from Verhaak et al identified a robust gene expression-based molecular classification that subdivided glioblastoma into proneural, neural, classical, and mesenchymal subtypes, with differential response to intensive treatments and proneural glioblastoma showing a trend toward longer survival.<sup>75</sup> However, the identification of reliable predictive biomarkers of response for glioblastoma is still elusive.

Conducting RCTs in patients affected by glioblastoma is a hard task because this tumor is infrequent and its rarity contributes to a paucity of funding for developing new drugs.<sup>76</sup> Furthermore, cognitive and motor impairment due to the disease itself makes it more difficult than for other cancers to enroll patients and make them strictly adhere to study protocols. Additionally, most available treatments prevent patients from entering many studies on recurrent glioblastoma, due to their exclusion criteria. Thus, the main strength of this NMA is that it provides evidence of comparisons of different therapeutic options which were mostly not (and likely will not be) compared in RCTs. At the same time, the major limitation is that we could not include some treatments that are conventionally used in relapsing/refractory glioblastoma (eg, PVC or platinum-based regimens), because approximately half of the initially selected studies were not linkable, due to heterogeneity in treatment strategies or unavailability of data required for statistical analyses. The latter issue is not surprising, considering that a significant number of trials were of phase II, and these trials are often underpowered and/or not designed to assess survival endpoints such as OS. However, restricting our search only to phase III trials would have significantly limited the possibility of developing an adequate network for our analyses. A possible solution might have been to have no





**Figure 4.** Forest plots of PFS and ORR of all included regimens for relapsed/refractory glioblastoma compared to lomustine monotherapy. (A) A forest plot including the logHR of PFS of each treatment vs lomustine monotherapy. Central dots represent posterior medians; thin lines represent 95% CrI, while thicker ones represent 80% CrI. Log scale was adopted to graphically represent the 95% CrI. The first column of values on the right reports the logHR with 95% CrI, the second column reports HR for PFS with 95% CrI. Statistically significant results according to Bayesian posterior medians and 95% CrI are highlighted by asterisks. (B) A forest plot including the logOR for ORR of each treatment vs lomustine monotherapy. Central dots represent posterior medians; lines represent 95% CrI. Log scale was adopted to graphically represent the 95% CrI. The first column of values on the right reports the logOR with 95% CrI, and the second column reports OR with 95% CrI. Statistically significant results according to Bayesian posterior medians and 95% CrI are highlighted by asterisks. Abbreviations: BEVA, bevacizumab; CARBO, carboplatin; CED, cediranib; CrI, credible interval; DASA, dasatinib; ENZA, enzastaurin; ERC1671, sitoiganap; ETO, etoposide; GALU, galunisertib; GEFI, gefitinib; HR, hazard ratio; IRINO, irinotecan; LD, low dose; LOM, lomustine; LOM90, lomustine at a dose of 90mg/m<sup>2</sup>; NIVO, nivolumab; NOVOTTF, NovoTTF-100A; ONAR, onartuzumab; OR, odds ratio; ORR, overall response rate; PFS, progression-free survival; RADIO, radiotherapy. REGO, regorafenib; RINDO, rindopepimut; TEMO, temozolomide; TREB, trebananib; VB-111, ofranergene obadenovec; VOR, vorinostat.



**Figure 5.** Global risk of bias analysis.

restriction for first-line setting trials, however, we chose to conduct our analyses in a more homogeneous setting, which is, by contrast, an important strength of our NMA. Another important limitation derives from WHO reclassifying CNS tumors in 2021. Since then, the *IDH1/2*-mutant entities are no longer considered as GB.<sup>77</sup> The most relevant consequence is the fact that many trial results are partially affected by the presence of *IDH*-mutant disease. Nonetheless, the approval of currently available therapeutic choices is based on the results of studies conducted before this paradigmatic change, including the ones that could be included in this NMA. Moreover, in 29.2% of the included studies, the mutational status was known and the proportion of *IDH*-mutant cases went from none to 18.1%, with a median of 6.9%. Considering the general low proportion of cases and their better prognosis compared to pure glioblastoma, it is unlikely that our results could be dramatically affected by this specific issue. However, it should be also considered that for most studies the population had not been molecularly characterized with respect to *MGMT* promoter methylation and *EGFRvIII* status. As a consequence, some population heterogeneity has to be considered when analyzing this study's results. Another limitation is that we could not provide a network for toxicities due to the heterogeneity of side effects reporting in distinct clinical trials. Finally, we also point out that NMA shares the same limitations as standard pairwise meta-analyses.<sup>78</sup>

To the best of our knowledge, while this is not the first NMA in the setting of relapsing/refractory glioblastoma, it is the most updated, also including immune-checkpoint inhibitor nivolumab, which was missing in previous studies, as well as the only published randomized study testing re-irradiation in a refractory scenario.<sup>79,80</sup> No significant inconsistency was found in our analytical models, the internal validity of the eligible studies was successfully assessed with the most appropriate risk of bias analysis<sup>81</sup> and results were methodologically reliable, being also coherent with previous efforts.<sup>79,80</sup> However, we believe that where our study mostly succeeds, is in pointing out the intrinsic limitations of published literature in glioblastoma, where most studies are underpowered, have varying inclusion criteria and primary endpoints, and are no longer adapted to the most updated WHO classification. Hence, given all these considerations, the poor response, and the scarce OS improvements provided by all of the available therapeutic options, recruiting in clinical trials should be always considered the preferential approach. Furthermore, the

incorporation of next-generation sequencing and proteomic platforms in clinical trials for patient selection or stratification, or the development of clinical trials with Bayesian adaptive design to expedite the identification of promising drugs, as elegantly done with the GBM AGILE trial,<sup>70</sup> might represent a paradigmatic change that we strongly need, in order to develop more effective treatments to tackle refracting/relapsing glioblastoma.

## Acknowledgments

Francesco Schettini is supported by a Rio Hortega clinical scientist contract from the Instituto de Salud Carlos III (ISCIII, CM22/00073). Opinions and hypotheses generated are solely of the article's authors. Francesco Schettini would also like to express his gratitude to Prof. Alfredo Marinelli from the University of Naples Federico II for the inspiring and thought-provoking conversations held in the distant year 2018, which continue to influence some of the conclusions drawn in this work. This study was supported by Mednote, a spin-off of the University of Trieste.

## Author contributions

All authors conceived the study. Francesco Schettini and Victoria Buché independently performed the literature search and Daniele Generali was consulted in case of controversy. Francesco Schettini and Victoria Buché collected the data from retrieved studies. Sergio Venturini digitalized the Kaplan-Meier curves and calculated the hazard ratios for the survival endpoints when unavailable from published abstracts or articles. Francesco Schettini and Daniele Generali approved the final list of included studies. Sergio Venturini built the networks and performed the statistical analyses. Francesco Schettini, Sergio Venturini, Estela Pineda, and Daniele Generali wrote the first manuscript draft. All authors revised and accepted the final version of the manuscript.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Conflicts of interest

Francesco Schettini reports honoraria from Novartis, Gilead, and Daiichi-Sankyo for educational events/materials, advisory

role for Pfizer, and travel expenses from Novartis, Gilead and Daiichi-Sankyo. Daniele Generali declares personal fees for educational events by Novartis, Lilly, Pfizer, Daiichi-Sankyo, and Roche; research funds from AstraZeneca, Novartis, and LILT. The authors have declared no conflict of interest.

## Data availability

The data used for the analyses reported in this study are publicly available from published literature. No proprietary codes were used in the statistical analyses.

## Supplementary material

Supplementary material is available at *The Oncologist* online.

## References

- Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. *Cancer Epidemiol Biomarkers Prev.* 2014;23:1985-1996. <https://doi.org/10.1158/1055-9965.EPI-14-0275>
- Stöckelmaier L, Renovan M, König J, et al. Therapy for recurrent high-grade gliomas: results of a prospective multicenter study on health-related quality of life. *World Neurosurg.* 2017;102:383-399. <https://doi.org/10.1016/j.wneu.2017.02.061>
- Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014;25:93-101.
- Nabors LB, Portnow J, Baehring J, et al. *Central Nervous System Cancers, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.* Last accessed August 16, 2023. <https://www.nccn.org/guidelines/guidelines-detail?category=1&cid=1425>
- Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. *J Clin Oncol.* 2022;40:403-426. <https://doi.org/10.1200/JCO.21.02036>
- Lau D, Magill ST, Aghi MK. Molecularly targeted therapies for recurrent glioblastoma: current and future targets. *Neurosurg Focus.* 2014;37:E15. <https://doi.org/10.3171/2014.9.FOCUS14519>
- Stupp R, Hegi ME, Mason WP, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol.* 2009;10:459-466. [https://doi.org/10.1016/S1470-2045\(09\)70025-7](https://doi.org/10.1016/S1470-2045(09)70025-7)
- Dias S, Ades A, Welton N, Jansen J, Sutton A. *Network Meta-Analysis for Decision-Making* | Wiley [Internet], 1st ed. John Wiley and Sons; 2018 [cited June 1, 2021]. Available at: <https://www.wiley.com/en-gb/Network+Meta+Analysis+for+Decision+Making-p-9781118647509>
- Mbuagbaw L, Rochweg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. *Syst Rev.* 2017;6:79. <https://doi.org/10.1186/s13643-017-0473-z>
- Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol.* 1990;8(7):1277-1280. <https://doi.org/10.1200/JCO.1990.8.7.1277>
- Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol.* 2010;28:1963-1972. <https://doi.org/10.1200/JCO.2009.26.3541>
- Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res Methodol.* 2012;12:9. <https://doi.org/10.1186/1471-2288-12-9>
- Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility. *Stat Comput.* 2000;10:325-337.
- Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health.* 2011;14:429-437. <https://doi.org/10.1016/j.jval.2011.01.011>
- Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. *Value Health.* 2011;14:417-428. <https://doi.org/10.1016/j.jval.2011.04.002>
- Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. *Stat Sci.* 1992;7:457-511.
- Lynch S. *Introduction to Applied Bayesian Statistics and Estimation for Social Scientists.* 1st ed. Springer-Verlag; 2007.
- Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med.* 2015;162:777-784. <https://doi.org/10.7326/M14-2385>
- Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods.* 2012;3:98-110. <https://doi.org/10.1002/jrsm.1044>
- Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med.* 2010;29:932-944. <https://doi.org/10.1002/sim.3767>
- R Core Team. *R: A Language and Environment for Statistical Computing.* R Foundation for Statistical Computing; 2021. URL <https://www.R-project.org/>
- Higgins JPT, Savović J, Page MJ et al. Chapter 8: Assessing risk of bias in a randomized trials In: Higgins J, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions, 5.1.* The Cochrane Collaboration, 2011. Available at <http://handbook.cochrane.org>.
- The Cochrane Collaboration. *Review Manager (Rev Man).* The Nordic Cochrane Center; 2014.
- Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *J Clin Oncol.* 2013;31:3212-3218. <https://doi.org/10.1200/JCO.2012.47.2464>
- Bogdahn U, Hau P, Stockhammer G, et al; Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. *Neuro-Oncology.* 2011;13:132-142. <https://doi.org/10.1093/neuonc/noq142>
- Boiardi A, Silvani A, Milanese I, Broggi G, Fariselli L. Efficacy of “8-drugs-in-one-day” combination in treatment of recurrent GBM patients. *J Neurooncol.* 1992;12:153-158. <https://doi.org/10.1007/BF00172666>
- Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. *J Clin Oncol.* 2010;28:4601-4608. <https://doi.org/10.1200/JCO.2009.27.1932>
- Brandes AA, Carpentier AF, Kesari S, et al. A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. *Neuro-Oncology.* 2016;18:1146-1156. <https://doi.org/10.1093/neuonc/now009>
- Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. *Lancet.* 1995;345:1008-1012. [https://doi.org/10.1016/s0140-6736\(95\)90755-6](https://doi.org/10.1016/s0140-6736(95)90755-6)
- Brown N, McBain C, Nash S, et al. Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. *PLoS*

- One.* 2016;11:e0156369-e0156315. <https://doi.org/10.1371/journal.pone.0156369>
31. Cloughesy T, Finocchiaro G, Belda-Iniesta C, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methylase. *J Clin Oncol.* 2017;35:343-351. <https://doi.org/10.1200/JCO.2015.64.7685>
  32. Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. *J Neurooncol.* 2010;96:393-402. <https://doi.org/10.1007/s11060-009-9976-3>
  33. Field KM, Simes J, Nowak AK, et al; CABARET/COGNO investigators. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. *Neuro-Oncology.* 2015;17:1504-1513. <https://doi.org/10.1093/neuonc/nov104>
  34. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol.* 2009;27:4733-4740. <https://doi.org/10.1200/JCO.2008.19.8721>
  35. Gilbert MR, Pugh SL, Aldape K, et al. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. *J Neurooncol.* 2017;131:193-199. <https://doi.org/10.1007/s11060-016-2288-5>
  36. Hiesiger EM, Green SB, Shapiro WR, et al. Results of a randomized trial comparing intraarterial cisplatin and intravenous Penu for the treatment of primary brain-tumors in adults - brain-tumor cooperative group trial 8420a. *J Neurooncol.* 1995;25:143-154. <https://doi.org/10.1007/BF01057758>
  37. Kunwar S, Chang S, Westphal M, et al; PRECISE Study Group. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. *Neuro-Oncology.* 2010;12:871-881. <https://doi.org/10.1093/neuonc/nop054>
  38. Prados MD, Schold SC Jr, Fine HA, et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. *Neuro-Oncology.* 2003;5:96-103.
  39. Reardon DA, Desjardins A, Peters K, et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. *J Neurooncol.* 2011;103:371-379. <https://doi.org/10.1007/s11060-010-0403-6>
  40. Robins HI, Zhang P, Gilbert MR, et al. A randomized phase III study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. *J Neurooncol.* 2016;126:309-316. <https://doi.org/10.1007/s11060-015-1966-z>
  41. Schiff D, Kesari S, De Groot J, et al. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. *Invest New Drugs.* 2015;33:247-253. <https://doi.org/10.1007/s10637-014-0186-2>
  42. Tsien CI, Pugh SL, Dicker AP, et al. NRG oncology/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. *J Clin Oncol.* 2023;41:1285-1295. <https://doi.org/10.1200/JCO.22.00164>
  43. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomized phase III trial of a novel treatment modality. *Eur J Cancer (Oxford, England: 1990).* 2012;48:2192-2202. <https://doi.org/10.1016/j.ejca.2012.04.011>
  44. Taal W, Oosterkamp HM, Walenkamp AME, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. *Lancet Oncol.* 2014;15:943-953. [https://doi.org/10.1016/S1470-2045\(14\)70314-6](https://doi.org/10.1016/S1470-2045(14)70314-6)
  45. Van Den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. *J Clin Oncol.* 2009;27:1268-1274. <https://doi.org/10.1200/JCO.2008.17.5984>
  46. Weathers S-P, Han X, Liu DD, et al. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. *J Neurooncol.* 2016;129:487-494. <https://doi.org/10.1007/s11060-016-2195-9>
  47. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. *J Clin Oncol.* 2010;28:1168-1174. <https://doi.org/10.1200/JCO.2009.23.2595>
  48. Wick W, Fricke H, Junge K, et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. *Clin Cancer Res.* 2014;20:6304-6313. <https://doi.org/10.1158/1078-0432.CCR-14-0951-T>
  49. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. *N Engl J Med.* 2017;377:1954-1963. <https://doi.org/10.1056/NEJMoa1707358>
  50. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer.* 2000;83:588-593. <https://doi.org/10.1054/bjoc.2000.1316>
  51. Brandes AA, Gil-Gil M, Saran F, et al. A randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma. *Oncologist.* 2019;24:521-528. <https://doi.org/10.1634/theoncologist.2018-0290>
  52. Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. *JAMA Oncol.* 2020;6:1003-1010. <https://doi.org/10.1001/jamaoncol.2020.1024>
  53. Bota DA, Chung J, Dandekar M, et al. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. *CNS Oncol.* 2018;7:CNS22. <https://doi.org/10.2217/cns-2018-0009>
  54. Reardon DA, Lassman AB, Schiff D, et al. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. *Cancer.* 2018;124:1438-1448. <https://doi.org/10.1002/cncr.31172>
  55. Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet Oncol.* 2019;20:110-119. [https://doi.org/10.1016/S1470-2045\(18\)30675-2](https://doi.org/10.1016/S1470-2045(18)30675-2)
  56. Bergman D, Modh A, Schultz L, et al. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma. *J Neurooncol.* 2020;148:353-361. <https://doi.org/10.1007/s11060-020-03526-4>
  57. Duerinck J, Du Four S, Bouttens F, et al. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. *J Neurooncol.* 2018;136:115-125. <https://doi.org/10.1007/s11060-017-2629-z>
  58. Chen H, Kuhn J, Lamborn KR, et al. Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. *Neurooncol. Adv.* 2020;2:vdaa124. <https://doi.org/10.1093/oaajnl/vdaa124>
  59. Cloughesy TF, Petrecca K, Walbert T, et al. Effect of vocimagene amiretrorepevec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. *JAMA Oncol.* 2020;6:1939-1946. <https://doi.org/10.1001/jamaoncol.2020.3161>
  60. Cloughesy TF, Brenner A, de Groot JF, et al; GLOBE Study Investigators. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients

- with recurrent glioblastoma (GLOBE). *Neuro Oncol.* 2020;22:705-717. <https://doi.org/10.1093/neuonc/noz232>
61. Reardon DA, Desjardins A, Vredenburgh JJ, et al; ReACT trial investigators. Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. *Clin Cancer Res.* 2020;26:1586-1594. <https://doi.org/10.1158/1078-0432.CCR-18-1140>
  62. Puduvalli VK, Wu J, Yuan Y, et al. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. *Neuro Oncol.* 2020;22:1505-1515. <https://doi.org/10.1093/neuonc/noaa062>
  63. Galanis E, Anderson SK, Twohy EL, et al. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. *Cancer.* 2019;125:3790-3800. <https://doi.org/10.1002/cncr.32340>
  64. Lee EQ, Zhang P, Wen PY, et al. NRG/RTOG 1122: a phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. *Cancer.* 2020;126:2821-2828. <https://doi.org/10.1002/cncr.32811>
  65. Narita Y, Arakawa Y, Yamasaki F, et al. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. *Neuro Oncol.* 2019;21:348-359. <https://doi.org/10.1093/neuonc/noy200>
  66. Nayak L, Molinaro AM, Peters K, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. *Clin Cancer Res.* 2021;27:1048-1057. <https://doi.org/10.1158/1078-0432.CCR-20-2500>
  67. Rosenthal M, Clement PM, Campone M, et al. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. *ESMO Open.* 2020;5:e000672. <https://doi.org/10.1136/esmoopen-2020-000672>
  68. Van Den Bent M, Eoli M, Sepulveda JM, et al. INTELLANCE 2/ EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. *Neuro Oncol.* 2020;22:684-693. <https://doi.org/10.1093/neuonc/noz222>
  69. Horbinski C, Nabors LB, Portnow J, et al. NCCN guidelines® insights: central nervous system cancers, version 2.2022. *J Natl Compr Canc Netw.* 2023;21:12-20. <https://doi.org/10.6004/jnccn.2023.0002>
  70. Wen P, Alexander B, Berry D, et al. CTNI-85. GBM agile platform trial for newly diagnosed and recurrent GBM: results of first experimental arm, regorafenib. *Neuro-Oncology.* 2023;25:v97-v98. <https://doi.org/10.1093/neuonc/noad179.0366>
  71. Bouchè V, Aldegheri G, Donofrio C, et al. BRAF signaling inhibition in glioblastoma: which clinical perspectives? *Front Oncol.* 2021 [cited August 15, 2023];11. Available at: <https://pubmed.ncbi.nlm.nih.gov/34804975/>
  72. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med.* 2018;378:731-739. <https://doi.org/10.1056/NEJMoa1714448>
  73. Doebele RC, Drilon A, Paz-Ares L, et al; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol.* 2020;21:271-282. [https://doi.org/10.1016/S1470-2045\(19\)30691-6](https://doi.org/10.1016/S1470-2045(19)30691-6)
  74. The Cancer Genome Atlas (TCGA) Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature.* 2008;455:1061-1068.
  75. Verhaak R, Hoadley K, Purdom E, et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. *Cancer Cell.* 2010;17:98.
  76. Madsen H, Hellwinkel JE, Graner MW. Clinical trials in glioblastoma — designs and challenges. In: Terry L, ed. *Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor.* InTech; 2015:277-308.
  77. Louis DN, Perry A, Wesseling P, et al. 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol.* 2021;23:1231-1251.
  78. Greenland S. Can meta-analysis be salvaged? *Am J Epidemiol.* 1994;140:783-787. <https://doi.org/10.1093/oxfordjournals.aje.a117326>
  79. McBain C, Lawrie TA, Rogozińska E, et al. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. *Cochrane Database Syst Rev.* 2021;5:CD013579. <https://doi.org/10.1002/14651858.CD013579.pub2>
  80. Schritz A, Aouali N, Fischer A, et al. Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma. *Neurooncol Adv.* 2021;3:vdab052. <https://doi.org/10.1093/nojnl/vdab052>
  81. Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011] [Internet]. The Cochrane Collaboration. Available at: <http://handbook.cochrane.org>